Ann: Webinar CHM Transforms Portfolio, page-25

PH was asked if they were considering a capital raise at the AGM.. he shot that down and said they are not considering it at the moment.

I think that puts it to bed, but agree that they'll need some cash injected one way or another mid 2022.

But my eye is not on the capital raise... rather its on the cohort 2 read-out.. and before that, the two new clinical sites opening up for our CLTX trial in the US which will make cohort 3 and 4 recruit much quicker.

I'm expecting by the time we hit SNO 2022.. they'll be presenting cohort 3 data.. which in my mind, is likely going to be the dose we take into phase 2.

I share the excitement that Jen showed when presenting the new NK platform.. though the market sold it down, that's out of the company's control.. all they can do is keep making progress and they've just laid the foundations for a next generation play, post CAR-T. So we are now hedged against a potential scenario where CAR-T is displaced by NK technology, as we'll already be years down the path of developing our own unique CAR-NK assets which may well be combined with our CAR T (if shown to be efficacious and safe), or used standalone.